Provided by Tiger Fintech (Singapore) Pte. Ltd.

Foghorn Therapeutics Inc.

6.19
0.0000
Post-market: 6.420.2300+3.72%19:55 EDT
Volume:82.02K
Turnover:502.88K
Market Cap:345.04M
PE:-4.62
High:6.39
Open:6.21
Low:6.00
Close:6.19
Loading ...

Foghorn Therapeutics Price Target Maintained With a $13.00/Share by HC Wainwright & Co.

Dow Jones
·
30 Apr

Foghorn Therapeutics: Buy Rating Backed by Innovative Oncology Approaches and Promising Clinical Developments

TIPRANKS
·
30 Apr

Analysts Are Bullish on Top Healthcare Stocks: Option Care Health (OPCH), Foghorn Therapeutics (FHTX)

TIPRANKS
·
30 Apr

Foghorn Therapeutics announces new preclinical data at AACR

TIPRANKS
·
29 Apr

Foghorn Therapeutics Presents Preclinical Data at AACR 2025

TIPRANKS
·
29 Apr

Foghorn Therapeutics Presents New Preclinical Data on Selective Smarca2 Inhibitor Fhd-909 and Selective Cbp and Selective Ep300 Degrader Programs and Provides Pipeline Update

THOMSON REUTERS
·
29 Apr

Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update

GlobeNewswire
·
29 Apr

Foghorn Therapeutics initiated with an Outperform at Citizens JMP

TIPRANKS
·
23 Apr

Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting

GlobeNewswire
·
26 Mar

Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform

Business Wire
·
25 Mar

BRIEF-Foghorn Therapeutics Files Prospectus For Issuance & Sale Of Shares Of Up To $100 Million From Time To Time

Reuters
·
21 Mar

Foghorn Therapeutics-Files Prospectus for Issuance & Sale of Shares of up to $100 Mln From Time to Time

THOMSON REUTERS
·
21 Mar

Promising Advancements and Strategic Collaborations Position Foghorn Therapeutics as a Strong Buy

TIPRANKS
·
08 Mar

Foghorn Therapeutics Price Target Maintained With a $13.00/Share by HC Wainwright & Co.

Dow Jones
·
07 Mar

Promising Potential of Foghorn Therapeutics’ FHD-909 Drives Buy Rating Amid Strategic Advances

TIPRANKS
·
07 Mar

Foghorn Therapeutics Reports Progress and Financial Stability

TIPRANKS
·
07 Mar

Foghorn Therapeutics Inc. reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
07 Mar

Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue Estimates

Zacks
·
07 Mar

Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook

GlobeNewswire
·
07 Mar

Foghorn Therapeutics Inc. expected to post a loss of 33 cents a share - Earnings Preview

Reuters
·
03 Mar